Orifarm Group AS - Strategic SWOT Analysis Review

December 2021 | 30 pages | ID: OCD444D0E83EN
GlobalData

Abstracts

Orifarm Group AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Orifarm Group A/S (Orifarm Group) is a parallel importer and supplier of pharmaceutical products. It comprises of several companies engaged in the import, manufacture, re-packaging, distribution, registration and commercialization of pharmaceuticals in the UK, Germany and Czech Republic, among others. The company parallel imports pharmaceuticals from European (EU) countries that are sold in Sweden, Finland, Holland, Denmark, Norway, Germany and the UK. Orifarm Group also sells prescription and over-the-counter (OTC) products in the Nordics under Taek Gult and Tank Gult brands. Orifarm Group is headquartered in Odense, Denmark.

Orifarm Group AS Key Recent Developments

Sep 16,2020: Class 2 FMD medicines recall, parallel distributed medicines, multiple products, EL (20)A/45
Apr 24,2020: Takeda to sell OTC and non-core assets to Orifarm for $670m

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Orifarm Group A/S - Key Facts
Orifarm Group A/S - Key Employees
Orifarm Group A/S - Key Employee Biographies
Orifarm Group A/S - Key Operational Employees
Orifarm Group A/S - Major Products and Services
Orifarm Group A/S - History
Orifarm Group A/S - Company Statement
Orifarm Group A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Orifarm Group A/S - Business Description
Business Segment: Generics
Overview
Performance
Business Segment: Parallel Import
Overview
Performance
Orifarm Group A/S - SWOT Analysis
SWOT Analysis - Overview
Orifarm Group A/S - Strengths
Orifarm Group A/S - Weaknesses
Orifarm Group A/S - Opportunities
Orifarm Group A/S - Threats
Orifarm Group A/S - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Orifarm Group A/S, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Orifarm Group A/S, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Orifarm Group A/S, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Sep 16, 2020: Class 2 FMD medicines recall, parallel distributed medicines, multiple products, EL (20)A/45
Apr 24, 2020: Takeda to sell OTC and non-core assets to Orifarm for $670m

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Orifarm Group A/S, Key Facts
Orifarm Group A/S, Key Employees
Orifarm Group A/S, Key Employee Biographies
Orifarm Group A/S, Key Operational Employees
Orifarm Group A/S, Major Products and Services
Orifarm Group A/S, History
Orifarm Group A/S, Subsidiaries
Orifarm Group A/S, Key Competitors
Orifarm Group A/S, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Orifarm Group A/S, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Orifarm Group A/S, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Orifarm Group A/S, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Orifarm Group A/S, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021